The current status of imaging in anti-NGF clinical trials

Osteoarthritis and Cartilage

Volumn 23, Issue , 2015, Pages S3-S7

  Miller, C G ^a   Guermazi, A ^b   Roemer, F ^c  

^a BioClinica Inc   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

ANGF; Anti nerve growth factor; Anti NGF; Clinical trials; Medical imaging; Radiology; X ray

Indexed keywords

NERVE GROWTH FACTOR ANTIBODY; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR;

CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG SAFETY; HUMAN; JOINT RADIOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; ARTHROPATHY; CHEMICALLY INDUCED; OSTEOARTHRITIS; RADIOGRAPHY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; JOINT DISEASES; NERVE GROWTH FACTOR; OSTEOARTHRITIS;

EID: 84922665702     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2014.09.002     Document Type: Review

References (11)

1. Abdiche Y.N., Malashock D.S., Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci 2008, 17(8):1326-1335.
2. McMahon S.B., Bennett D.L.H., Priestley J.V., Shelton D.L. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med 1995, 1(8):774-780.
3. Brown M.T., Murphy F.T., Radin D.M., Davignon I., Smith M.D., West C.R. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. JPain Off J Am Pain Soc 2012, 13(8):790-798.
4. Brown M.T., Murphy F.T., Radin D.M., Davignon I., Smith M.D., West C.R. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum 2013, 65(7):1795-1803.
5. FDA. Food and Drug Administration Center for Drug Evaluation and Research. Arthritis Advisory Committee Meeting: March 12, 2012. Available from: (last accessed June 10, 2014). http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/ucm286552.htm.
6. Balanescu A.R., Feist E., Wolfram G., Davignon I., Smith M.D., Brown M.T., et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis 2013, 73:1665-1672.
7. Bapat A.A., Hostetter G., Von Hoff D.D., Han H. Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer 2011, 11(10):695-707.
8. Nagashima H., Suzuki M., Araki S., Yamabe T., Muto C. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage 2011, 19(12):1405-1412.
9. Schnitzer T.J., Ekman E.F., Spierings E.L., Greenberg H.S., Smith M.D., Brown M.T. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis 2014, Published Online First:13 March 2014.
10. Tiseo P.J., Kivitz A.J., Ervin J.E., Ren H., Mellis S.J. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. Pain 2014, 7:523-530.
11. FDA. Food and Drug Administration Center for Drug Evaluationand Research. Arthritis Advisory Committee Meeting: Feb 8, 2012. Available from: (last accessed June 10, 2014). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm295205.pdf.